The Clinical Research Unit of Bedrocan, a prominent manufacturer of pharmaceutical-grade medicinal cannabis, has been established with the aim of investigating the effects of its cannabis products. There has been a change from only funding outside research to carrying out internal studies. As a result, Bedrocan is proactive in learning about the safety and medicinal potential of cannabis-based drugs.
Clinical studies on medical cannabis
The Clinical Research Unit in Utrecht, Netherlands, under the direction of renowned cannabis researcher Matthijs Bossong, represents Bedrocan’s dedication to furthering scientific understanding in the field of medicinal cannabis. The corporation has been a consistent financial backer of outside researchers for many years. But Bedrocan hopes to assume the lead in directing cannabis research now that its research department has been established.
Mikael Kowal, Chief Scientific Officer, expressed his excitement for the debut. He said:
“These items are the subject of extensive global research, but the specific topics that are studied are determined by other scientists. We now take the initiative and carry out own research.”
This change enables Bedrocan to investigate the impacts of its two main medicines, Bedrocan® and Bediol®, in more detail under carefully monitored circumstances. As a result, it will provide insightful information about both possible hazards and their best utilization.
Approved by a Medical Ethics Committee, the pilot project will assess the risk factors related to cannabis usage, with a focus on reducing symptoms of anxiety and psychosis. Therefore, the goal of the research is to give patients and healthcare professionals with evidence-based recommendations for the safe and effective use of medicinal cannabis.
Future medical cannabis research
In the future, the Clinical study Unit plans to conduct a thorough study program aimed at relevant scientific questions, particularly chronic neuropathic pain. According to Matthijs Bossong’s explanation, “Medicinal cannabis has been shown to have potential benefits for a number of ailments, including chronic pain. The issue with cannabis-related clinical research, though, is that different trials show quite different results.” The research endeavours to mitigate the inherent variability in cannabis studies by the utilisation of Bedrocan’s standardised products. This will enhance the credibility of the findings and promote increased confidence among medical practitioners in the prescription of medicinal cannabis.
CEO Jaap Erkelens celebrated the Clinical Research Unit’s founding as a turning point in Bedrocan history.
“Bedrocan can now conduct targeted research into the effects of the cannabis products it produces on behalf of the Dutch government.”
He underscored the necessity of obtaining official recognition for the safety and effectiveness of these products, highlighting the firm’s steadfast dedication to maintaining the strictest regulatory compliance.
Bedrocan is undoubtedly a model of excellence in the manufacture of pharmaceutical-grade cannabis, having obtained EU GMP certification. Its cutting-edge facilities and persistent commitment to scientific rigor highlight its leadership position in the medical cannabis sector. Bedrocan is about to begin on a revolutionary path to advance scientific understanding, spur innovation, and ultimately improve patient care in the field of medicinal cannabis with the opening of its Clinical Research Unit.